Key Developments For SenoRx, Inc.
SenoRx, Inc. (SENO.O) (Consolidated Issue listed on NASDAQ Global Market)
SenoRx, Inc. Announces Poster Presentation On Interim Results of First 100 Patients In Contura MLB Registry Study Delivered At American Society For Radiology And Oncology (ASTRO)
SenoRx, Inc. announced that a poster presentation summarizing clinical findings of the first 100 patients in its Contura Multi-Lumen Balloon (MLB) registry study was delivered at the Annual Meeting of the American Society for Radiology and Oncology (ASTRO) on November 3, 2009 in Chicago, Illinois. The study, titled Initial Dosimetric Experience: Contura Multi-Lumen Balloon (MLB) Registry Trial, is designed to compare the dosimetric efficacy of Contura MLB with a single central lumen balloon device and to quantify the dosimetric improvement of multi-lumen use over single-lumen use. The Principal Investigators of the study are Drs. Frank A. Vicini, Douglas W. Arthur, Dorin Todor and Thomas B. Julian. Based on the first 100 patients, the authors preliminarily confirmed that without the dosimetric optimizing capabilities, the safe use of a single-lumen balloon is limited to patients with ideal cavity geometry and balloon symmetry. This initial data shows that the use of multiple, offset lumens allow the optimization of target coverage while minimizing dose to nearby skin and chest wall, thus creating a new improved dosimetric standard.
SenoRx, Inc. Lowers High End Of Prior FY 2009 Revenue Outlook To A Range In Line With Analysts' Estimates
SenoRx, Inc. announced that for fiscal 2009, it now expects revenues to be in the range of $56-$57 million. According to Reuters Estimates, analysts were expecting the Company to report revenues of $56 million for the same period.
SenoRx, Inc. Appoints John T. Buhler President and Chief Operating Officer
SenoRx, Inc. announced the appointment of John T. Buhler to the newly created position of President and Chief Operating Officer.
SenoRx, Inc. Reaffirms FY 2009 Revenue Guidance
SenoRx, Inc. announced that it expects it could be challenging to achieve the top of its projected revenue range. However, the Company continues to believe that the impact of modestly lower revenues can be offset by positive trends in expected gross margin. SenoRx reaffirmed its current estimate that revenues for fiscal 2009 will be in a range of $56-$59 million. According to Reuters Estimates, analysts were expecting the Company to report revenue of $57 million for fiscal 2009.
SenoRx, Inc. Appoints Lloyd H. Malchow As Chairman-Form 8-K
SenoRx, Inc. reported in its Form 8-K that the Board has appointed Lloyd H. Malchow, current President, Chief Executive Officer and Director, as Chairman.
